This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Q1 Earnings Scorecard and Analyst Reports for Netflix, Costco & Others
by Sheraz Mian
In addition to new research reports on 16 major stocks, including Netflix (NFLX), Costco (COST) and others, we also have real-time Q1 earnings scorecard today.
What's in Store for Dow ETFs in Q1 Earnings?
by Sweta Killa
With most blue-chip companies' earnings scheduled over the coming weeks, investors should closely monitor the movement of the Dow ETF.
Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus
by Sweta Killa
Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.
Stock Market News for Apr 15, 2020
by Zacks Equity Research
Benchmarks closed higher on Tuesday as investors remained optimistic that the U.S. economy may open soon. The coronavirus pandemic had compelled the government to take protective measures including lockdowns.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Buy Abbott (ABT) Stock Ahead of Earnings on Coronavirus Testing Push?
by Benjamin Rains
The FDA has approved two different Abbott coronavirus tests. So now the question for investors is should they consider buying ABT shares with the firm set to report its Q1 fiscal 2020 financial results on Thursday, April 16?
JPMorgan, Wells Fargo Miss; J&J Beats in Q1
by Mark Vickery
Market futures are up this morning, eager to erase yesterday's losses and apparently not impeded by what they've seen from earnings reports thus far today.
Major Banks Report Q1 Earnings
by Zacks Equity Research
Major Banks Report Q1 Earnings
J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 13.30% and 7.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Begins Study on Galidesivir for Coronavirus Infection
by Zacks Equity Research
BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
Big Week of Q1 Earnings Coming Up
by Mark Vickery
Starting with the big banks and moving to companies working of a vaccine for COVID-19, we'll hope for the best and expect the worst.
JPMorgan, Bank of America, Citigroup, Johnson & Johnson and Kansas City Southern are part of Zacks Earnings Preview
by Zacks Equity Research
JPMorgan, Bank of America, Citigroup, Johnson & Johnson and Kansas City Southern are part of Zacks Earnings Preview
Gilead Reports Promising Data on Experimental Coronavirus Drug
by Zacks Equity Research
Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.
Q1 Earnings in Focus
by Zacks Equity Research
Q1 Earnings in Focus
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate
by Zacks Equity Research
Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.
J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies